Literature DB >> 20820129

Clinical aggressiveness of incidental and non-incidental thyroid cancer.

A Ciampolillo1, M Bellacicco, A Natalicchio, A Pezzolla, P Trerotoli, L Grammatica, G Achille, F Giorgino.   

Abstract

BACKGROUND: With the increasing use of thyroid ultrasound, the recognition of thyroid nodules in a large proportion of apparently healthy subjects has become common. Because also the papillary thyroid microcarcinomas (PTMC) are being increasingly discovered, it is important to ascertain whether PTMC may exhibit heterogenous clinical features, associated with different aggressiveness. AIM: We retrospectively examined 122 subjects [98 female (80.3%), and 24 male (19.7%)] with thyroid cancer to find potential clinical and pathological findings that could be predictive of clinically aggressive behavior.
RESULTS: Twenty of the 31 patients with true incidental cancer (64.5%) in comparison to 20 of the 91 patients with non-incidental cancer (21.9%) had a diameter <10 mm, and this difference was statistically significant (p<0.0001). There was a statistically significant association between size and invasiveness because 19.3% of invasive cancers were <10 mm whereas 44.6% of non-invasive cancers were <10 mm (p=0.005). The relationship between incidental discovery and invasiveness was also evaluated, but the proportion of incidental invasive cancer (19.3%) was not significantly different from that of incidental non-invasive cancer (30.8%). In the multivariate analysis, only size <10 mm (odds ratio=0.35, p=0.013) and papillary vs other histotypes (odds ratio=0.35, p=0.04) were statistically significant protective factors against invasiveness.
CONCLUSIONS: a) Incidentally discovered thyroid cancers are more frequently microcarcinomas; b) there appears to be no difference in terms of invasive behavior between incidental and non-incidental thyroid cancer; c) smaller tumor size emerges as a protective factor.

Entities:  

Mesh:

Year:  2010        PMID: 20820129     DOI: 10.3275/7254

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  Mediastinal lymph node involvement as the initial manifestation of occult thyroid cancer in the surgical treatment of lung cancer: report of a case.

Authors:  M Higashiyama; K Kodama; H Yokouchi; K Takami; K Motomura; H Inaji; H Koyama
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Authors:  G Tallini; M Santoro; M Helie; F Carlomagno; G Salvatore; G Chiappetta; M L Carcangiu; A Fusco
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

4.  Aggressive behavior of papillary microcarcinoma in a patient with Graves' disease initially presenting as cystic neck mass.

Authors:  M Braga; H Graf; A Ogata; J Batista; Neto C A Hakim
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

5.  Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma.

Authors:  Dong-Jun Lim; Ki-Hyun Baek; Youn-Soo Lee; Woo-Chan Park; Mee-Kyoung Kim; Moo-Il Kang; Hae-Myung Jeon; Jong-Min Lee; Bong Yun-Cha; Kwang-Woo Lee; Ho-Young Son; Sung-Koo Kang
Journal:  Thyroid       Date:  2007-09       Impact factor: 6.568

6.  Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.

Authors:  E Baudin; J P Travagli; J Ropers; F Mancusi; G Bruno-Bossio; B Caillou; A F Cailleux; J D Lumbroso; C Parmentier; M Schlumberger
Journal:  Cancer       Date:  1998-08-01       Impact factor: 6.860

Review 7.  Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.

Authors:  E L Mazzaferri; N Massoll
Journal:  Endocr Relat Cancer       Date:  2002-12       Impact factor: 5.678

8.  Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.

Authors:  Xiaolong Lee; Ming Gao; Yifeng Ji; Yang Yu; Ying Feng; Yigong Li; Yan Zhang; Wenyuan Cheng; Wenchuan Zhao
Journal:  Ann Surg Oncol       Date:  2008-11-26       Impact factor: 5.344

9.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.

Authors:  Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

10.  Prognostic parameters for recurrence of papillary thyroid microcarcinoma.

Authors:  Tae Yong Kim; Suck Joon Hong; Jung Min Kim; Won Gu Kim; Gyungyub Gong; Jin Sook Ryu; Won Bae Kim; Sung-Cheol Yun; Young Kee Shong
Journal:  BMC Cancer       Date:  2008-10-14       Impact factor: 4.430

View more
  1 in total

Review 1.  Observation for newly diagnosed micro-papillary thyroid cancer: is now the time?

Authors:  F Pacini
Journal:  J Endocrinol Invest       Date:  2014-10-26       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.